247results about How to "Has inhibitory activity" patented technology

The invention relates to a new process for preparing animal protolysate containing high calcium with complex enzyme hydrolysized chicken bone mud, which is characterized in that it comprises the following steps: disintegrating chicken bone ultramicroly to make bone mud, formulating bone mud suspending solution, heating under 80-100 Deg .C for 20-30 minutes, cooling to temperature proper for enzyme reaction, regulating pH value, adding complex enzyme for reacting for a certain time, then heating to 85-90 Deg. C and keeping for 10-20 minutes for sterilization, and getting product which is concentration of sepia, semitransparent or stramineous powder. The invention resolves problems of odour of raw material and bitter caused by enzymolysis, the product most of which is short peptide and free amino acid can be adsorbed easily by human body which increase comprehensive utilization ratio of product, and the product possess certain action for inhibiting angiotonin zymose.

The invention relates to a lactobacillus and in particular relates to a low-temperature resistant lactobacillus with ACE (angiotensin converting enzyme) inhibitory activity. The low-temperature resistant lactobacillus with the ACE inhibitory activity is lactobacillus plantarum I1 which is preserved in the China general microbiological culture collection center of which the preservation address is No.3, No1. yard, Beichen west road, Chaoyang District of Beijing, the preservation data is September 18th, 2012, and the preservation number is CGMCC No.6575; the lactobacillus plantarum I1 has the ACE inhibitory rate being 66%, can tolerate 6% of NaCl and 100mg/kg of nitrite, and can fast generate acid; the growing temperature of the lactobacillus plantarum I1 is 4-40 DEG C, and is suitable for low-temperature fermentation; and the low-temperature resistant lactobacillus has obvious protease activity and lipase activity, can not generate mucus, has an obvious antibacterial effect on staphylococcus aureus and colon bacillus, and can be used as a meat product leavening agent strain under a low-temperature condition.

The invention relates to 4'-amino-4'-dehydroxyl-oleandrin and 4'-amino-4'-dehydroxyl-odoroside A and use thereof. The invention provides a compound represented by the following general formula I shown in the description or pharmaceutically acceptable salts thereof, a preparation method therefor, a pharmaceutical composition containing the compound represented by the following general formula I shown in the description or pharmaceutically acceptable salts thereof and use thereof. The compound has inhibitory activity to the propagation of humanized tumor cell lines and can serve as a drug for treating malignant tumors.

A compound of the formula (I) wherein Z<4>, Z<5> and Z<9> each is independently carbon atom or nitrogen atom; Y is hydroxy, mercapto or amino; R is a group of the formula (II) (wherein C ring is nitrogen-containing heteroaryl) has an inhibitory activity against integrase.

The invention relates to novel benzanthracene cyclic compounds and a preparation method and use thereof. The benzanthracene cyclic compounds have the structure shown in a general formula I or II. The compounds can be used as topoisomerase inhibitors for preparing anti-tumor, cell growth-resistant, antibacterial and antimalarial medicaments. The invention also relates to a method for preparing the compounds. In the formula I, C1' and C3' have an S structure simultaneously, and in the formula II, C1' and C3' have an R structure simultaneously.

A streptomyces strain, and anti-kidney-cancer applications of piericidin metabolites thereof are disclosed. The streptomyces strain is streptomyces sp.HBERC-58855, and is deposited in the China Center for Type Culture Collection, in Wuhan University, Wuhan, China on April 20, 2017. The accession number of the streptomyces sp.HBERC-58855 is CCTCC NO:M 2017186. The 16sRNA nucleotide sequence of the streptomyces sp.HBERC-58855 is shown as SEQ ID NO:1. Piericidin compounds including piericidin A, piericidin A2, piericidin C2, IT-143-A, IT-143-B and piericidin s3a are extracted from the streptomyces sp.HBERC-58855 through fermentation for the first time, and are applied in preparation of anti-kidney-cancer medicines. Candidate compounds are provided for development of novel anti-kidney-cancer medicines. The streptomyces and the piericidin compounds are of great significance for marine microorganism medicine resource development.

The invention discloses a use of 4,7-dihydrotetrazyl[1,5-alpha]pyrimidine compound and its derivatives in preparation of a drug for prevention or treatment on cerebral hemorrhage. Through a self-created computer-assisted drug molecule design program and virtual screening, it is shown that the 4,7-dihydrotetrazyl[1,5-alpha]pyrimidine compound and its derivatives have a ROCK1 protein inhibitory activity and can be used for treating cerebral hemorrhage. Through further biological activity detection of the screened 4,7-dihydrotetrazyl[1,5-alpha]pyrimidine compound, it is shown that the screened 4,7-dihydrotetrazyl[1,5-alpha]pyrimidine compound has an obvious ROCK1 protein inhibitory activity and has good prevention and treatment effects in an atorvastatin-induced zebra fish cerebral hemorrhage model.

The invention provides an application of compounds Pyrrocidines in preparation of an anti-tuberculosis drug, namely, an application of the compounds Pyrrocidines, derivatives of the compound Pyrrocidines or pharmaceutically acceptable salts of the compounds Pyrrocidines as tyrosine phosphatase inhibitors or in preparation of the tyrosine phosphatase inhibitors. The compounds 19-O-methyl-pyrrrocidine B and pyrrrocidine B have inhibitory activity on mycobacterium tuberculosis tyrosine phosphatase B, and IC50 of the compounds is 3.9 mu M and 75.5 mu M respectively. The compounds can effectively inhibit dephosphorylation activity of the mycobacterium tuberculosis tyrosine phosphatase B and has the clinical application potential for tuberculosis treatment; besides, the compounds Pyrrocidines are natural-metabolism active micro-molecular products separated from microorganisms and can be produced through chemical synthesis and large-scale fermentation separation, the sources are abundant, the production cost is low, and the possibility of medicine preparation is high.

The invention discloses a pyrrolidine[3,4-d]pyrimidine derivative and a preparation method and an application thereof. The pyrrolidine[3,4-d]pyrimidine derivative is an inhibitor of a type I insulin-like growth factor receptor (IGF-1R), and has a good IGF-1R inhibiting function and a good cancer cell proliferation inhibiting function, so that the pyrrolidine[3,4-d]pyrimidine derivative can be taken as a therapeutic agent for treating tumors and relevant diseases.

The invention relates to 2-(thiazol-2-yl)imino-5-(benzylidene)thiazolidin-4-one shown as formulas I, II, III or IV or a mixture thereof, wherein R1 is selected from hydrogen, C1-C2 alkyl or C3-C4 straight-chain or branched chain alkyl, R2 is selected from hydrogen, C1-C2 alkyl or C3-C4 straight-chain or branched chain alkyl, X1-X5 are selected from hydrogen, C1-C2 alkyl, C3-C4 straight-chain or branched chain alkyl, nitro, amino or NHCOR, and R is selected from hydrogen, C1-C2 alkyl or C3-C4 straight-chain or branched chain alkyl. Applications of the 2-(thiazol-2-yl)imino-5-benzal thiazoline-4-one or the mixture thereof in preparation of neuraminidase inhibitors are also disclosed.

The invention relates to the technical field of biomedicine, in particular relates to a royal jelly polypeptide and application thereof. According to the invention, intestinal tract enzyme is extracted from a queen bee larva in vivo, and an in vivo enzymolysis environment of queen bee is simulated to carry out enzymolysis on royal jelly so as to obtain 1-3kDa of royal jelly polypeptide. The royal jelly polypeptide can be used for preparing an A beta inhibitor.

The invention discloses an indole derivative with a 1, 2, 4-oxadiazole structure, which has antibacterial activity, a preparation method thereof and application thereof in preparation of antibacterial medicines, belonging to the technical field of medicine synthesis. The compound has the structure as shown in the general formula I, wherein when an A ring is an aromatic ring, R1 and R2 are ortho-positions, meta-positions and para-substituted groups on the aromatic ring; and when the an A ring is a non-aromatic ring, both the R1 and R2 are hydrogen. The compound disclosed by the invention is a novel alkaloid compound which is synthesized for the first time; and the compound has certain inhibitory activity on methicillin-resistant staphylococcus aureus (MRSA), which is found for the first time in synthetic compound in vitro model testing experiments, and therefore, the compound has potential application prospects in preparation of antibacterial medicines and treatment of bacterial infection.

The present invention relates to a compound with 1,6-methylene-[10]-annulene basic skeleton. Said invention provides its structure formula. Said compound has the activity for inhibiting tumor cell, can be used for developing new anti-tumor medicine for curing cancer of lung, mammary cancer, liver cancer and leukemia, etc.